Yinglei Gao

449 total citations
21 papers, 296 citations indexed

About

Yinglei Gao is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Yinglei Gao has authored 21 papers receiving a total of 296 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Molecular Biology, 9 papers in Oncology and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Yinglei Gao's work include Fibroblast Growth Factor Research (4 papers), Cancer, Hypoxia, and Metabolism (4 papers) and Histone Deacetylase Inhibitors Research (4 papers). Yinglei Gao is often cited by papers focused on Fibroblast Growth Factor Research (4 papers), Cancer, Hypoxia, and Metabolism (4 papers) and Histone Deacetylase Inhibitors Research (4 papers). Yinglei Gao collaborates with scholars based in China, Norway and Australia. Yinglei Gao's co-authors include Jing Ai, Jian Ding, Meiyu Geng, Yi Chen, Xinying Yang, Peng Xia, Yanfen Fang, Yiming Sun, Qianqian Shen and Yinchun Ji and has published in prestigious journals such as Cancer Research, Journal of Medicinal Chemistry and Cancer Letters.

In The Last Decade

Yinglei Gao

21 papers receiving 291 citations

Peers

Countries citing papers authored by Yinglei Gao

Since Specialization

Citations

This map shows the geographic impact of Yinglei Gao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yinglei Gao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yinglei Gao more than expected).

Fields of papers citing papers by Yinglei Gao

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yinglei Gao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yinglei Gao. The network helps show where Yinglei Gao may publish in the future.

Co-authorship network of co-authors of Yinglei Gao

This figure shows the co-authorship network connecting the top 25 collaborators of Yinglei Gao. A scholar is included among the top collaborators of Yinglei Gao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yinglei Gao. Yinglei Gao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Discovery of Novel Tridentate Alkenyl Diacid Derivatives as Potent ATP Citrate Lyase Inhibitors for the Treatment of Hepatocellular Carcinoma 2025 ·Journal of Medicinal Chemistry ·Yiping Yang, (unknown), (unknown), (unknown), (unknown), Xinyu Sun, Qingbo Zhang, (unknown), Min Gu, Yinglei Gao, Mei Zhang, Jian Ding, Yi Chen, Jingya Li, Zhifu Xie, Yanfen Fang, Fajun Nan	1
2	HDAC inhibitor GCJ-490A modulates tumor microenvironment and synergizes with PD-1 antibody against breast and lung cancers in syngeneic murine models 2025 ·Acta Pharmacologica Sinica ·Wenxin Zhang, Ting He, Kun Fang, Yinglei Gao, Yiming Sun, Fajun Nan, Jian Ding, (unknown), Yanfen Fang	1
3	Dysregulation of iron homeostasis by TfR-1 renders EZH2 wild type diffuse large B-cell lymphoma resistance to EZH2 inhibition 2023 ·Acta Pharmacologica Sinica ·Yu Lei, Wang Yf, Jian Xiao, Qianqian Shen, (unknown), Yinglei Gao, (unknown), Jian Ding, (unknown), (unknown)	14
4	Identification of [1,2,4]Triazolo[4,3-a]pyrazine PARP1 inhibitors with overcome acquired resistance activities 2023 ·European Journal of Medicinal Chemistry ·Pingyuan Wang, (unknown), Yajing Wang, Shanshan Song, Yong Xi, Xinying Yang, Yanyan Shen, Yi Su, Yiming Sun, Yinglei Gao, Yi Chen, Jian Ding, Ze‐Hong Miao, Ao Zhang, Jin‐Xue He	7
5	Degradation of Cyclin-Dependent Kinase 9/Cyclin T1 by Optimized Microtubule-Associated Protein 1 Light Chain 3 Beta-Recruiting Coumarin Analogs 2023 ·Journal of Medicinal Chemistry ·Yanping Zeng, Jian Xiao, Yuanxin Xu, Wei Fan, (unknown), Yinglei Gao, Yi Chen, Youhong Hu	19
6	The HDAC inhibitor GCJ-490A suppresses c-Met expression through IKKα and overcomes gefitinib resistance in non-small cell lung cancer 2022 ·Cancer Biology and Medicine ·Ting He, Yinglei Gao, Yanfen Fang, Yangming Zhang, Shuwei Zhang, Fajun Nan, Jian Ding, (unknown)	11
7	¹⁸F-FDG PET as an imaging biomarker for the response to FGFR-targeted therapy of cancer cells via FGFR-initiated mTOR/HK2 axis 2022 ·Theranostics ·(unknown), Qinghe Zeng, (unknown), Peng Xia, Jing Gao, (unknown), Luting Wang, Yinglei Gao, Xiaoyu Zhou, (unknown), (unknown), (unknown), Hu Zhou, Jian Ding, Jing Ai, Ruimin Huang	6
8	Abstract 5436: HH2853 is a selective small molecular dual inhibitor of EZH1/2 with potent anti-tumor activities 2022 ·Cancer Research ·Xuxing Chen, Qianqian Shen, Zhao Zhao, (unknown), (unknown), Yinglei Gao, Lei Liu, Yixiang Zhang, Yi Chen, Leping Li	6
9	SAF-189s, a potent new-generation ROS1 inhibitor, is active against crizotinib-resistant ROS1 mutant-driven tumors 2020 ·Acta Pharmacologica Sinica ·(unknown), Yinchun Ji, (unknown), Peng Xia, Yinglei Gao, Yanfen Fang, (unknown), Weibo Wang, Jian Ding, Meiyu Geng, Jing Ai	13
10	Design, Synthesis, and Biological Evaluation of HSP90 Inhibitor–SN38 Conjugates for Targeted Drug Accumulation 2020 ·Journal of Medicinal Chemistry ·(unknown), Qianqian Shen, Yinglei Gao, Lei Wang, Yanfen Fang, Yi Chen, Wei Lü	23
11	EZH2 inhibitors abrogate upregulation of trimethylation of H3K27 by CDK9 inhibitors and potentiate its activity against diffuse large B-cell lymphoma 2019 ·Haematologica ·Shao Xie, Wei Fan, Yiming Sun, Yinglei Gao, Lulu Pan, Minjia Tan, Shudong Wang, Jian Ding, Yi Chen	7
12	Discovery of a series of dimethoxybenzene FGFR inhibitors with 5H-pyrrolo[2,3-b]pyrazine scaffold: structure–activity relationship, crystal structural characterization and in vivo study 2018 ·Acta Pharmaceutica Sinica B ·Wei Peng, Bo Liu, Ruifeng Wang, Yinglei Gao, Lanlan Li, Yuchi Ma, (unknown), Yue‐Lei Chen, Maosheng Cheng, Meiyu Geng, Jingkang Shen, Dongmei Zhao, Jing Ai, Bing Xiong	6
13	Discovery and optimization of a series of 3-substituted indazole derivatives as multi-target kinase inhibitors for the treatment of lung squamous cell carcinoma 2018 ·European Journal of Medicinal Chemistry ·Qi Wang, Yang Dai, Yinchun Ji, (unknown), (unknown), Danqi Chen, Yue‐Lei Chen, Peng Xia, Yinglei Gao, Xin Wang, Lin Chen, (unknown), Meiyu Geng, Jingkang Shen, Jing Ai, Bing Xiong	14
14	Decrease in phosphorylated ERK indicates the therapeutic efficacy of a clinical PI3Kα-selective inhibitor CYH33 in breast cancer 2018 ·Cancer Letters ·Xueling Liu, Yichao Xu, Yuxiang Wang, Yi Chen, Bobo Wang, Yi Wang, Yanhong Chen, (unknown), (unknown), Qingyang Ma, Yuchao Zhang, Yiming Sun, Yinglei Gao, Chunhao Yang, Jian Ding, Linghua Meng	18
15	Preclinical Evaluation of SCC244 (Glumetinib), a Novel, Potent, and Highly Selective Inhibitor of c-Met in MET-dependent Cancer Models 2017 ·Molecular Cancer Therapeutics ·Jing Ai, Yi Chen, Peng Xia, Yinchun Ji, Yong Xi, Yanyan Shen, Xinying Yang, Yi Su, Yiming Sun, Yinglei Gao, Yuchi Ma, Bing Xiong, Jingkang Shen, Jian Ding, Meiyu Geng	26
16	Evaluation of in vitro and in vivo activity of a multityrosine kinase inhibitor, AL3810, against human thyroid cancer 2017 ·Acta Pharmacologica Sinica ·Qin Xie, Hui Chen, Jing Ai, Yinglei Gao, Meiyu Geng, Jian Ding, Yi Chen	4
17	Combining 53BP1 with BRCA1 as a biomarker to predict the sensitivity of poly(ADP-ribose) polymerase (PARP) inhibitors 2017 ·Acta Pharmacologica Sinica ·Zhongmin Yang, Xuemei Liao, Yi Chen, Yanyan Shen, Xinying Yang, Yi Su, Yiming Sun, Yinglei Gao, Jian Ding, Ao Zhang, Jin‐Xue He, Ze‐Hong Miao	27
18	Design, Synthesis, and Pharmacological Evaluation of Novel Multisubstituted Pyridin-3-amine Derivatives as Multitargeted Protein Kinase Inhibitors for the Treatment of Non-Small Cell Lung Cancer 2017 ·Journal of Medicinal Chemistry ·Wei Zhu, Hui Chen, (unknown), Jiang Wang, Peng Xia, Xianjie Chen, Yinglei Gao, Chunpu Li, Yulong He, Jing Ai, Meiyu Geng, Mingyue Zheng, Hong Liu	20
19	An orally available tyrosine kinase ALK and RET dual inhibitor bearing the tetracyclic benzo[b]carbazolone core 2016 ·European Journal of Medicinal Chemistry ·Zilan Song, (unknown), Yinchun Ji, Xing Li, Yinglei Gao, Jing Ai, Meiyu Geng, Ao Zhang	12
20	Discovery of 3-(5′-Substituted)-Benzimidazole-5-(1-(3,5-dichloropyridin-4-yl)ethoxy)-1H-indazoles as Potent Fibroblast Growth Factor Receptor Inhibitors: Design, Synthesis, and Biological Evaluation 2016 ·Journal of Medicinal Chemistry ·Wei Yan, Xinyi Wang, Yang Dai, Bin Zhao, Xinying Yang, Jun Fan, Yinglei Gao, Fanwang Meng, Yuming Wang, Cheng Luo, Jing Ai, Meiyu Geng, Wenhu Duan	46

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact